Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 8Recruiting 2Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 135Other solid neoplasm 14Gastrointestinal 7Genitourinary 5Head & Neck 4Gynecologic 4CNS 4Tumor-Agnostic 3Dermatologic 3Breast 3Sarcoma 1Lymphoid 1

Conditions

Osteosarcoma 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 26Temozolomide 23Doxorubicin 22Radiotherapy 21Filgrastim 19Ifosfamide 15pazopanib 14Gemcitabine 14Etoposide 13Bevacizumab 13Irinotecan 12Cisplatin 12Magnetic Resonance Spectroscopy 11Imatinib Mesylate 11Granulocyte Colony-Stimulating Factor 11Carboplatin 11Radiation 9Methotrexate 9pembrolizumab 8fludarabine phosphate 8Rituximab 8Paclitaxel 8Docetaxel 8Cyclosporine 8Busulfan 8Antilymphocyte Serum 8fludarabine 7Vincristine 7Radiotherapy, Intensity-Modulated 7Mycophenolic Acid 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Pemetrexed × Sarcoma × Clear all
NCT04861948 2022-10-04

IBI188 Combination Therapy in Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Terminated
9 enrolled
SarcomaThoracic

Adenocarcinoma of Lung, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡